VIRAX BIOLABS GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6139 USD | +0.64% |
|
-11.03% | -57.95% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | 8.56K | Capitalization | 10.81M |
|---|---|---|---|---|---|
| Net income 2022 | -1M | Net income 2023 | -5M | EV / Sales 2022 * | - |
| Net cash position 2022 | 21.76K | Net cash position 2023 | 9.26M | EV / Sales 2023 | 182 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-1.35
x | Employees | 11 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.2% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.64% | ||
| 1 week | -11.03% | ||
| Current month | -2.56% | ||
| 1 month | -25.13% | ||
| 3 months | -22.29% | ||
| 6 months | -75.84% | ||
| Current year | -57.95% |
1 week
0.60
0.68
1 month
0.600.83
Current year
0.601.43
1 year
0.605.45
3 years
0.60290.00
5 years
0.60290.00
10 years
0.60290.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Foster
CEO | Chief Executive Officer | 37 | 12-12-31 |
Jason Davis
DFI | Director of Finance/CFO | 52 | 22-05-01 |
Mark Ternouth
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nelson Haight
BRD | Director/Board Member | 59 | - |
Evan Norton
BRD | Director/Board Member | 49 | - |
James Foster
CEO | Chief Executive Officer | 37 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.6139 | +0.64% | 30,984 |
| 24-05-02 | 0.61 | -6.01% | 9,446 |
| 24-05-01 | 0.649 | +3.02% | 53,836 |
| 24-04-30 | 0.63 | +0.21% | 12,793 |
| 24-04-29 | 0.6287 | -8.89% | 18,360 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotes
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -57.95% | 1.45M | |
| +25.69% | 47.9B | |
| +47.58% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- VRAX Stock